Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Pine Pharmaceuticals, LLC

Pine Pharmaceuticals, LLC Recalls

All product recalls associated with Pine Pharmaceuticals, LLC.

Get alerts for this brand

Recall Summary

Total Recalls

1000

Past Year

304

Class I (Serious)

Most Recent

Nov 2025

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 621–640 of 4747 recalls

Endophth Kit (Pine) – Sterility Concern (2023)

Lack of Assurance of Sterility

Class IIModerate

FDAOct 2, 2023Nationwide• Pine Pharmaceuticals, LLC

Cefuroxime Syringe (Pine) – Sterility Concern (2023)

Lack of Assurance of Sterility

Class IIModerate

FDAOct 2, 2023Nationwide• Pine Pharmaceuticals, LLC

Calcium Chloride IV Solution (Pine Pharmaceuticals) – sterility concern (2023)

Lack of Assurance of Sterility

Class IIModerate

1...30 313233 34...238

Page 32 of 238Next

FDA

Oct 2, 2023

Nationwide

• Pine Pharmaceuticals, LLC

Vancomycin Intraocular Solution (Pine Pharmaceuticals) – sterility concern (2023)

Lack of Assurance of Sterility

Class IIModerate

FDAOct 2, 2023Nationwide• Pine Pharmaceuticals, LLC

Bevacizumab Injection Solution (Pine Pharmaceuticals) – sterility concern (2023)

Lack of Assurance of Sterility

Class IIModerate

FDAOct 2, 2023Nationwide• Pine Pharmaceuticals, LLC

Moxifloxacin Solution (Pine) – Sterility Concern (2023)

Lack of Assurance of Sterility

Class IIModerate

FDAOct 2, 2023Nationwide• Pine Pharmaceuticals, LLC

Lidocaine-Phenylephrine Vial (Pine) – Sterility Concern (2023)

Lack of Assurance of Sterility

Class IIModerate

FDAOct 2, 2023Nationwide• Pine Pharmaceuticals, LLC

TPC Ophthalmic Drops (Pine Pharmaceuticals) – sterility concern (2023)

Lack of Assurance of Sterility

Class IIModerate

FDAOct 2, 2023Nationwide• Pine Pharmaceuticals, LLC

Calcium Gluconate Inhalation Solution (Pine Pharmaceuticals) – sterility concern (2023)

Lack of Assurance of Sterility

Class IIModerate

FDAOct 2, 2023Nationwide• Pine Pharmaceuticals, LLC

Tropi-Phen Ophthalmic Solution (Pine Pharmaceuticals) – sterility concern (2023)

Lack of Assurance of Sterility

Class IIModerate

FDAOct 2, 2023Nationwide• Pine Pharmaceuticals, LLC

Liposomal Multivitamins (Solaray) – Packaging concern (2023)

This recall involves Solaray Liposomal Women's in 60 and 120 count, Solaray Universal Multivitamin in 60 and 120 count, and Solaray Liposomal Women's 50+ Multivitamin in 120 count. The bottles are a clear silver color with white pop top lids. The white label on the front of the bottles displays the Solaray logo, product name, product type and size count. The 60 count bottles are contained in cartons, which are substantially similar in appearance to the bottles inside. All lots are included in the recall. Name Count SKU Solaray Liposomal Women's 60 076280193251 Solaray Liposomal Women's 120 076280339536 Solaray Universal Multivitamin 60 076280640168 Solaray Universal Multivitamin 120 076280830385 Solaray Liposomal Women's 50+ Multivitamin 120 076280154832

CPSCSep 28, 2023Nationwide• Nutraceutical Corporation, of Salt Lake City, Utah

RapidPoint 500e System (Siemens) – Drug Interference Risk (2023)

There are potential drug interferences from Perhexiline Maleate or Atomoxetine Hydrochloride that may cause falsely elevated sodium results reported on the RAPIDPoint 500 and RAPIDPoint 500e Blood Gas Systems. The erroneous sodium levels with positive bias may lead to unrecognized hyponatremia and/or the inappropriate treatment of hypernatremia may lead to iatrogenic hyponatremia, resulted in a delay in patient diagnosis and optimal patient management.

FDASep 26, 2023Nationwide• Siemens Healthcare Diagnostics Inc

RapidPoint 500 System (Siemens) – Drug Interference Risk (2023)

FDASep 26, 2023Nationwide• Siemens Healthcare Diagnostics Inc

Oxybutynin Chloride 10 mg (Zydus) – Dissolution Failure (2023)

Failed Dissolution Specifications

Class IIModerate

FDASep 21, 2023Nationwide• Zydus Pharmaceuticals (USA) Inc

LeadCare II Test Kit (Magellan) – Plastic Cap Issue (2023)

During an internal audit a small percentage (<10%) of plastic caps used to close the treatment reagent tubes were found to not meet the minimum dimensional lip requirement and may have inadequate cap-to-tube seals. Manufacturing with these caps may result in cap-to-tube seals that allow leaking of HCl or may result in cap-to-tube seals that allow evaporation of treatment reagent. The consequence of this would be a change in the volume of treatment reagent and a change in the ratios of either added patient sample or control material to treatment reagent. The result of this might be a falsely elevated result (e.g., a patient false positive [PATFP] result or a Controls Out of Range-High [COOR-Hi] result).

FDASep 19, 2023Nationwide• Magellan Diagnostics, Inc.

VITROS Lipase Slides (Ortho-Clinical) – Result Bias (2023)

Laceration Risk

Products 1668409 and 8297749 may contain VITROS Lipase Slides with an abnormality which could cause -46% to +86% bias in lipase results depending on how the slides are used. Falsely low levels could result in a missed or delayed diagnosis of acute pancreatitis and may lead to diagnostic confusion in the setting of acute abdominal symptoms. Falsely elevated levels would not result in patient harm but may cause diagnostic confusion and a delay in accurate diagnosis of a patient with abdominal pain.

FDASep 12, 2023CA, CO, FL +9 more• Ortho-Clinical Diagnostics, INc.